losartan has been researched along with Fatty Liver, Nonalcoholic in 13 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this randomised controlled trial was to assess whether treatment with Losartan for 96 weeks slowed, halted or reversed the progression of fibrosis in patients with non-alcoholic steatohepatitis (NASH)." | 5.24 | A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. ( Anstee, QM; Barnes, J; Burt, AD; Bury, Y; Day, CP; Goudie, N; Mann, D; McColl, E; McPherson, S; Steen, N; Stewart, S; Stocken, DD; Tiniakos, D; Wilkinson, J; Wilkinson, N, 2017) |
| "Male C57BL/6 J mice with high fat-high sucrose diet (HF-HSD) induced NASH, obesity, insulin resistance and hypercholesterolemia were subjected to dietary intervention (switch from HF-HSD to normal chow diet (NCD)) (n = 9), continuation HF-HSD together with losartan (30 mg/kg/day) (n = 9) or continuation HF-HSD only (n = 9) for 8 weeks." | 3.85 | Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice. ( Bedossa, P; Cammue, B; Cassiman, D; Nevens, F; Spincemaille, P; Thevissen, K; Van den Berghe, G; van der Merwe, S; van Pelt, J; Vander Elst, I; Vanhorebeek, I; Verbeek, J; Windmolders, P, 2017) |
| "Although viral hepatocellular carcinoma (HCC) is declining, nonviral HCC, which often is the end stage of nonalcoholic or alcoholic steatohepatitis (NASH, ASH), is on an upward trajectory." | 1.91 | Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells. ( Chamseddine, S; Gu, L; Huang, JY; Karin, M; Kaseb, AO; Lee, M; Mohamed, YI; Nguyen, A; Pandit, SK; Ryujin, NT; Shalapour, S; Xiao, L; Zhu, Y, 2023) |
| "The enalapril treatment, but not aliskiren or losartan, was effective in improving leptin, glucose intolerance, IR, hepatic steatosis, and triglycerides and in preventing increased hepatic protein levels of phosphoenolpyruvate carboxykinase (PEPCK), glucose 6-phosphatase (G6Pase), and glucose transporter-2 (GLUT-2)." | 1.40 | Comparative effects of the renin-angiotensin system blockers on nonalcoholic fatty liver disease and insulin resistance in C57BL/6 mice. ( Aguila, MB; Batista, Tde M; Frantz, ED; Mandarim-de-Lacerda, CA; Penna-de-Carvalho, A, 2014) |
| "ARB markedly inhibited liver fibrosis development along with suppression of the number of Ac-HSC and TGF-β." | 1.39 | Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis. ( Aihara, Y; Douhara, A; Fukui, H; Kaji, K; Kawaratani, H; Moriya, K; Namisaki, T; Noguchi, R; Shirai, Y; Yoshiji, H, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Vos, MB | 1 |
| Van Natta, ML | 1 |
| Blondet, NM | 1 |
| Dasarathy, S | 1 |
| Fishbein, M | 1 |
| Hertel, P | 1 |
| Jain, AK | 1 |
| Karpen, SJ | 1 |
| Lavine, JE | 1 |
| Mohammad, S | 1 |
| Miriel, LA | 1 |
| Molleston, JP | 1 |
| Mouzaki, M | 1 |
| Sanyal, A | 1 |
| Sharkey, EP | 1 |
| Schwimmer, JB | 1 |
| Tonascia, J | 1 |
| Wilson, LA | 1 |
| Xanthakos, SA | 1 |
| Namisaki, T | 4 |
| Kaji, K | 3 |
| Shimozato, N | 1 |
| Kaya, D | 1 |
| Ozutsumi, T | 1 |
| Tsuji, Y | 1 |
| Fujinaga, Y | 1 |
| Kitagawa, K | 1 |
| Furukawa, M | 1 |
| Sato, S | 1 |
| Sawada, Y | 1 |
| Nishimura, N | 2 |
| Takaya, H | 1 |
| Okura, Y | 1 |
| Seki, K | 1 |
| Kawaratani, H | 4 |
| Moriya, K | 3 |
| Noguchi, R | 4 |
| Asada, K | 1 |
| Akahane, T | 1 |
| Mitoro, A | 1 |
| Yoshiji, H | 4 |
| Gu, L | 1 |
| Zhu, Y | 1 |
| Lee, M | 1 |
| Nguyen, A | 1 |
| Ryujin, NT | 1 |
| Huang, JY | 1 |
| Pandit, SK | 1 |
| Chamseddine, S | 1 |
| Xiao, L | 1 |
| Mohamed, YI | 1 |
| Kaseb, AO | 1 |
| Karin, M | 1 |
| Shalapour, S | 1 |
| Bo, L | 1 |
| Wei, L | 1 |
| Shi, L | 1 |
| Luo, C | 1 |
| Gao, S | 1 |
| Zhou, A | 1 |
| Mao, C | 1 |
| McPherson, S | 1 |
| Wilkinson, N | 1 |
| Tiniakos, D | 1 |
| Wilkinson, J | 1 |
| Burt, AD | 1 |
| McColl, E | 1 |
| Stocken, DD | 1 |
| Steen, N | 1 |
| Barnes, J | 1 |
| Goudie, N | 1 |
| Stewart, S | 1 |
| Bury, Y | 1 |
| Mann, D | 1 |
| Anstee, QM | 1 |
| Day, CP | 1 |
| Yang, YY | 1 |
| Lee, PC | 1 |
| Huang, YT | 1 |
| Lee, WP | 1 |
| Kuo, YJ | 1 |
| Lee, KC | 1 |
| Hsieh, YC | 1 |
| Lee, TY | 1 |
| Lin, HC | 1 |
| Kitade, M | 2 |
| Aihara, Y | 3 |
| Douhara, A | 2 |
| Fukui, H | 3 |
| Frantz, ED | 1 |
| Penna-de-Carvalho, A | 1 |
| Batista, Tde M | 1 |
| Aguila, MB | 1 |
| Mandarim-de-Lacerda, CA | 1 |
| Verbeek, J | 1 |
| Spincemaille, P | 1 |
| Vanhorebeek, I | 1 |
| Van den Berghe, G | 1 |
| Vander Elst, I | 1 |
| Windmolders, P | 1 |
| van Pelt, J | 1 |
| van der Merwe, S | 1 |
| Bedossa, P | 1 |
| Nevens, F | 1 |
| Cammue, B | 1 |
| Thevissen, K | 1 |
| Cassiman, D | 1 |
| Ikenaka, Y | 1 |
| Shirai, Y | 2 |
| Yoshii, J | 1 |
| Yanase, K | 1 |
| Tsujimoto, T | 1 |
| Torres, DM | 1 |
| Jones, FJ | 1 |
| Shaw, JC | 1 |
| Williams, CD | 1 |
| Ward, JA | 1 |
| Harrison, SA | 1 |
| Corey, KE | 1 |
| Chalasani, N | 1 |
3 trials available for losartan and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Randomized placebo-controlled trial of losartan for pediatric NAFLD.
Topics: Adolescent; Angiotensin Receptor Antagonists; Blood Pressure; Child; Double-Blind Method; Female; Hu | 2022 |
A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Double-Blind Method; Drug Administration Sched | 2017 |
Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Biopsy; Drug Therapy, Combination; | 2011 |
10 other studies available for losartan and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2022 |
Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells.
Topics: Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Humans; Liver Cirrhosis; Liver Neoplasms; Los | 2023 |
Altered local RAS in the liver increased the risk of NAFLD in male mouse offspring produced by in vitro fertilization.
Topics: Animals; Diet, High-Fat; Female; Fertilization in Vitro; Glucose; Humans; Lipids; Liver; Losartan; M | 2023 |
Involvement of the HIF-1α and Wnt/β-catenin pathways in the protective effects of losartan on fatty liver graft with ischaemia/reperfusion injury.
Topics: Animals; beta Catenin; Diet, High-Fat; Fatty Liver; Glycoproteins; Hypoxia-Inducible Factor 1, alpha | 2014 |
Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticarcinogenic Agents; Antineoplastic Combined C | 2014 |
Comparative effects of the renin-angiotensin system blockers on nonalcoholic fatty liver disease and insulin resistance in C57BL/6 mice.
Topics: Adipose Tissue; Amides; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Enalapril; | 2014 |
Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; CD36 Antigens; Collagen Type I, alpha 1 Chain; Dru | 2017 |
Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats.
Topics: Administration, Oral; Angiogenesis Inhibitors; Angiotensin II; Angiotensin II Type 1 Receptor Blocke | 2011 |
Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?
Topics: Fatty Liver; Female; Humans; Losartan; Male; Metformin; Non-alcoholic Fatty Liver Disease; Rosiglita | 2011 |
Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Communication; Disease Models | 2013 |